Clinical pharmacist participates in the pharmacological monitoring of a patient with severe osteoporosis treated with denosumab
A 73 year old female patient with severe osteoporosis underwent hip arthroplasty and was then treated with denosumab for osteoporosis.After 6 days,the patient complained of convulsions in the lower limbs and her blood calcium content was 2.0 mmol/L after follow-up examination.The clinical pharmacists judged that this adverse reaction was associated with denosumab injection by considering her symptoms and medication history,and promptly adjusted the medical prescription,added calcium gluconate granules and osteotriol gel pills to promote calcium absorption,and her hypocalcaemia was finally corrected.Clinical pharmacists actively participate in the development of treatment plans and provide comprehensive pharmacy services to promote the therapeutic efficacy of patients with severe high-risk osteoporosis,ensure the safety of their medication,and improve their prognosis and quality of life.
万方数据
维普
